(688180)"Shanghai Junshi Biosciences Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688180 · · 11 pages · Chinese
Shanghai Junshi Biosciences Co., Ltd. on 6ix
Earlier from Shanghai Junshi Biosciences
- (688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of the Grant of Regular Approval by the National Medical Products Administration for Toripalimab for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma After Failure of Platinum-based Chemotherapy
- (688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of the Acceptance of the Marketing Application for Toripalimab Injection (Subcutaneous Injection) for a New Indication in First-line Treatment of HER2-Expressing Urothelial Carcinoma
- Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
- Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
Follow Shanghai Junshi Biosciences into a list and get an email when it puts out news.
Follow Shanghai Junshi Biosciences